Therapeutic potential of PPARγ activation in stroke

PPAR Research

Volumn , Issue , 2008, Pages

  Vemuganti, Raghu ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; BRAIN DAMAGE; CLINICAL TRIAL; DRUG EFFECT; HOSPITAL ADMISSION; HUMAN; LIPID METABOLISM; NEUROPROTECTION; NONHUMAN; REVIEW; STROKE;

EID: 43949086052     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/461981     Document Type: Review

References (111)

1. Berger J., Moller D. E., The mechanisms of action of PPARs Annual Review of Medicine 2002 53 409 435
2. Moreno S., Farioli-Vecchioli S., Cerù M. P.
3. de Lera A. R., Bourguet W., Altucci L., Gronemeyer H., Design of selective nuclear receptor modulators: RAR and RXR as a case study Nature Reviews Drug Discovery 2007 6 10 811 820
4. Mangelsdorf D. J., Thummel C., Beato M., The nuclear receptor superfamily: the second decade Cell 1995 83 6 835 839
5. Cunard R., Ricote M., DiCampli D., Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors Journal of Immunology 2002 168 6 2795 2802
6. Argmann C. A., Cock T.-A., Auwerx J.
7. Schoonjans K., Staels B., Auwerx J., The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation Biochimica et Biophysica Acta 1996 1302 2 93 109
8. Lehrke M., Lazar M. A.
9. Desvergne B.
10. Bell-Parikh L. C., Ide T., Lawson J. A., McNamara P., Reilly M., FitzGerald G. A.
11. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR- α,-β, and-γ in the adult rat Endocrinology 1996 137 1 354 366
12. Bernardo A., Levi G., Minghetti L.
13. Sakamoto J., Kimura H., Moriyama S., Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochemical and Biophysical Research Communications 2000 278 3 704 711
14. Kudzma D. J., Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus American Journal of Managed Care 2002 8, supplement 16 S472 S482
15. Bogan A. A.
16. Shiraki T., Kamiya N., Shiki S., Kodama T. S., Kakizuka A., Jingami H.
17. Chang F., Jaber L. A., Berlie H. D., O'Connell M. B.
18. Olsen S. T., Bruhn P., Oberg G., An ischemic penumbra as the cause of neurologic deficit in humans Journal of Cerebral Blood Flow & Metabolism 1985 S7 S8
19. Camarata P. J., Heros R. C., Latchaw R. E., "Brain attack": the rationale for treating stroke as a medical emergency Neurosurgery 1994 34 1 144 158
20. Lucas S. M., Rothwell N. J., Gibson R. M., The role of inflammation in CNS disease and injury British Journal of Pharmacology 2006 147 S1 S232 S240
21. Lipton P., Ischemic cell death in brain neurons Physiological Reviews 1999 79 4 1431 1568
22. Dirnagl U., Iadecola C., Moskowitz M. A., Pathobiology of ischaemic stroke: an integrated view Trends in Neurosciences 1999 22 9 391 397
23. Stanimirovic D.
24. Iadecola C.
25. Satriotomo I., Bowen K. K., Vemuganti R.
26. Raghavendra Rao V. L.
27. Planas A. M., Soriano M. A., Berruezo M., Induction of Stat3, a signal transducer and transcription factor, in reactive microglia following transient focal cerebral ischaemia European Journal of Neuroscience 1996 8 12 2612 2618
28. Lu A.
29. Iadecola C.
30. Kapadia R., Tureyen K., Bowen K. K., Kalluri H., Johnson P. F., Vemuganti R.
31. Feurstein G. Z., Wang X. K., Barone G. C., Ginsberg M. D., Bogousslavsky J., Inflammatory mediators of ischemic injury: cytokine gene regulation in stroke Cerebrovascular Disease: Pathophysiology, Diagnosis and Management 1998 Malden, Mass, USA Blackwell 507 531
32. Tureyen K., Kapadia R., Bowen K. K., Peroxisome proliferator-activated receptor- γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents Journal of Neurochemistry 2007 101 1 41 56
33. Shih A. Y., Li P., Murphy T. H.
34. Tanaka K.
35. Bernaudin M., Nedelec A.-S., Divoux D., MacKenzie E. T., Petit E., Schumann-Bard P., Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain Journal of Cerebral Blood Flow and Metabolism 2002 22 4 393 403
36. Collino M.
37. Wayman N. S., Hattori Y., Mcdonald M. C., Ligands of the peroxisome proliferator-activated receptors (PPAR- γ and PPAR- α) reduce myocardial infarct size The FASEB Journal 2002 16 9 1027 1040
38. Liu H.-R., Tao L., Gao E., Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion Cardiovascular Research 2004 62 1 135 144
39. Aoun P., Watson D. G., Simpkins J. W.
40. Landreth G. E.
41. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K.
42. Jiang C., Ting A. T., Seed B.
43. Mehta J. L.
44. Chen K., Li D., Zhang X., Hermonat P. L., Mehta J. L.
45. Ito H., Nakano A., Kinoshita M., Matsumori A.
46. Yan W.-W., Zhou Z.-G.
47. Michalik L.
48. Sattar N.
49. Cuzzocrea S.
50. Marx N.
51. Cuzzocrea S.
52. Rossi A., Kapahi P., Natoli G., Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I κ B kinase Nature 2000 403 6765 103 108
53. Sivarajah A., Chatterjee P. K., Patel N. S. A., Agonists of peroxisome-proliferator activated receptor- γ reduce renal ischemia/reperfusion injury American Journal of Nephrology 2003 23 4 267 276
54. Tilley S. L., Coffman T. M., Koller B. H., Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes Journal of Clinical Investigation 2001 108 1 15 23
55. Straus D. S., Pascual G., Li M., 15-Deoxy- Δ12,14 -prostaglandin J2 inhibits multiple steps in the NF- κ B signaling pathway Proceedings of the National Academy of Sciences of the United States of America 2000 97 9 4844 4849
56. Delerive P., Fruchart J.-C., Staels B., Peroxisome proliferator-activated receptors in inflammation control Journal of Endocrinology 2001 169 3 453 459
57. Linnik M. D., Zobrist R. H., Hatfield M. D., Koroshetz W. J., Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats Stroke 1993 24 12 2002 2009
58. Yrjänheikki J., Tikka T., Keinänen R., Goldsteins G., Chan P. H., Koistinaho J.
59. Jiang J., Wang W., Sun Y. J., Hu M., Li F., Zhu D. Y.
60. Khan M.
61. Shen J., Zhang H., Lin H., Su H., Xing D., Du L.
62. Kagansky N., Levy S., Knobler H., The role of hyperglycemia in acute stroke Archives of Neurology 2001 58 8 1209 1212
63. Ogata T., Miyauchi T., Sakai S., Irukayama-Tomobe Y., Goto K., Yamaguchi I., Stimulation of peroxisome-proliferator-activated receptor α (PPAR α) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts Clinical Science 2002 103, supplement 48 284S 288S
64. Victor N. A., Wanderi E. W., Gamboa J., Altered PPAR γ expression and activation after transient focal ischemia in rats European Journal of Neuroscience 2006 24 6 1653 1663
65. Park E. Y., Cho I. J., Kim S. G.
66. Sundararajan S.
67. Zhao Y., Patzer A., Gohlke P., Herdegen T.
68. Luo Y., Yin W., Signore A. P., Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor- γ agonist rosiglitazone Journal of Neurochemistry 2006 97 2 435 448
69. Allahtavakoli M.
70. Chu K., Lee S.-T., Koo J.-S., Peroxisome proliferator-activated receptor- γ -agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia Brain Research 2006 1093 1 208 218
71. Shimazu T., Inoue I., Araki N., A peroxisome proliferator-activated receptor- γ agonist reduces infarct size in transient but not in permanent ischemia Stroke 2005 36 2 353 359
72. Pascual G., Fong A. L., Ogawa S., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR- γ Nature 2005 437 7059 759 763
73. Takata Y., Kitami Y.
74. Feinstein D. L.
75. Dello Russo C.
76. Young P. W., Buckle D. R., Cantello B. C. C., Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ Journal of Pharmacology and Experimental Therapeutics 1998 284 2 751 759
77. Park S.-W., Yi J.-H., Miranpuri G., Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats Journal of Pharmacology and Experimental Therapeutics 2007 320 3 1002 1012
78. Deplanque D., Gelé P., Pétrault O., Peroxisome proliferator-activated receptor- α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment Journal of Neuroscience 2003 23 15 6264 6271
79. Bordet R.
80. Collino M.
81. Hwang J., Kleinhenz D. J., Lassègue B., Griendling K. K., Dikalov S., Hart C. M.
82. Geremia E., Baratta D., Zafarana S., Antioxidant enzymatic systems in neuronal and glial cell-enriched fractions of rat brain during aging Neurochemical Research 1990 15 7 719 723
83. Moreno S., Mugnaini E., Ceru M. P., Immunocytochemical localization of catalase in the central nervous system of the rat Journal of Histochemistry and Cytochemistry 1995 43 12 1253 1267
84. Girnun G. D., Domann F. E., Moore S. A., Robbins M. E. C.
85. Herrera B., Álvarez A. M., Sánchez A., Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor β in fetal hepatocytes The FASEB Journal 2001 15 3 741 751
86. Perez-Pinzon M. A.
87. Lin T.-N.
88. Sulejczak D., Czarkowska-Bauch J., Macias M., Skup M.
89. Charbonnel B.
90. Dormandy J. A.
91. Huang Y.
92. Yki-Järvinen H.
93. Lee J., Reding M.
94. Diab A., Deng C., Smith J. D., Peroxisome proliferator-activated receptor- γ agonist 15-deoxy- Δ12,14 -prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis Journal of Immunology 2002 168 5 2508 2515
95. Kiaei M.
96. Mrak R. E.
97. Culman J., Zhao Y., Gohlke P., Herdegen T.
98. Feinstein D. L.
99. Breidert T.
100. Steinman L., Martin R., Bernard C., Conlon P., Oksenberg J. R., Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy Annual Review of Neuroscience 2002 25 491 505
101. Schütz B., Reimann J., Dumitrescu-Ozimek L., The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice Journal of Neuroscience 2005 25 34 7805 7812
102. Pompl P. N., Ho L., Bianchi M., McManus T., Qin W., Pasinetti G. M., A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis The FASEB Journal 2003 17 6 725 727
103. McTigue D. M.
104. Park E. J., Park S. Y., Joe E.-H., Jou I.
105. Neve B. P., Corseaux D., Chinetti G., PPAR α agonists inhibit tissue factor expression in human monocytes and macrophages Circulation 2001 103 2 207 212
106. Spencer N. F. L., Poynter M. E., Im S.-Y., Daynes R. A., Constitutive activation of NF- κ B in an animal model of aging International Immunology 1997 9 10 1581 1588
107. Kieć-Wilk B.
108. Aspey B. S., Ehteshami S., Hurst C. M., Pereira S., Harrison M. J. G., Effect of bezafibrate on the sequelae of acute experimental focal cerebral ischaemia Journal of Neurology Neurosurgery and Psychiatry 1989 52 12 1432 1434
109. O'Rourke F., Dean N., Akhtar N., Shuaib A., Current and future concepts in stroke prevention Canadian Medical Association Journal 2004 170 7 1123 1133
110. Iwashita A.
111. Ding G., Cheng L., Qin Q., Frontin S., Yang Q.